| scholarly article | Q13442814 |
| P50 | author | Marylyn D. Ritchie | Q18631934 |
| Dawood Darbar | Q38327125 | ||
| Alison Motsinger-Reif | Q52448430 | ||
| Dan Roden | Q58973971 | ||
| P2093 | author name string | James V Gainer | |
| P2860 | cites work | KCNQ1 gain-of-function mutation in familial atrial fibrillation | Q24338486 |
| Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation | Q24534117 | ||
| Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study | Q29614968 | ||
| Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation | Q30306103 | ||
| ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writi | Q30940275 | ||
| The natural history of lone atrial fibrillation. A population-based study over three decades | Q34186025 | ||
| Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study | Q34201000 | ||
| Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease | Q68408728 | ||
| Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study | Q70026998 | ||
| Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism | Q72034083 | ||
| Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy | Q72235427 | ||
| A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease | Q72541490 | ||
| Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications | Q72566134 | ||
| Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration | Q72575475 | ||
| Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone | Q72819723 | ||
| Locus for atrial fibrillation maps to chromosome 6q14-16 | Q73469209 | ||
| Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure | Q73684390 | ||
| Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart | Q73744475 | ||
| Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation | Q73782374 | ||
| Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation | Q73854861 | ||
| Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans | Q73889054 | ||
| C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation | Q77337410 | ||
| ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans | Q77554983 | ||
| Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure | Q80998610 | ||
| An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels | Q34262228 | ||
| Renin-angiotensin system gene polymorphisms and atrial fibrillation | Q34306157 | ||
| Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring | Q34327141 | ||
| Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death | Q34335461 | ||
| New ideas about atrial fibrillation 50 years on. | Q34503407 | ||
| Histological substrate of atrial biopsies in patients with lone atrial fibrillation | Q34742809 | ||
| Familial atrial fibrillation is a genetically heterogeneous disorder. | Q35160348 | ||
| The impact of renin-angiotensin system polymorphisms on physiological and pathophysiological processes in humans | Q35748420 | ||
| Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation | Q36525558 | ||
| Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method | Q39802766 | ||
| PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1) | Q40421372 | ||
| Identification of a genetic locus for familial atrial fibrillation | Q40900354 | ||
| Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation | Q43738125 | ||
| Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure | Q43803594 | ||
| C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation | Q43854958 | ||
| Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation | Q43904609 | ||
| Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension | Q43940854 | ||
| Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure | Q44025903 | ||
| Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation | Q44035539 | ||
| Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. | Q44064962 | ||
| Angiotensin-converting enzyme (ACE) I/D genotype and renal ACE gene expression | Q44152987 | ||
| Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide | Q44342393 | ||
| Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation | Q44487854 | ||
| Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation | Q44739491 | ||
| A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction | Q44836568 | ||
| Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation | Q44961647 | ||
| Association of angiotensin converting enzyme gene polymorphisms with left ventricular hypertrophy | Q46683608 | ||
| Left ventricular size, mass, and function in relation to angiotensin-converting enzyme gene polymorphism in humans | Q47369600 | ||
| Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension. | Q51027011 | ||
| Symptomatic burden as an endpoint to evaluate interventions in patients with atrial fibrillation. | Q51975703 | ||
| Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. | Q52429603 | ||
| The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. | Q53510743 | ||
| Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction | Q57606113 | ||
| P433 | issue | 6 | |
| P921 | main subject | Atrial Fibrillation | Q815819 |
| P304 | page(s) | 743-749 | |
| P577 | publication date | 2007-02-09 | |
| P1433 | published in | Heart Rhythm | Q2058605 |
| P1476 | title | Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation | |
| P478 | volume | 4 |
| Q36280780 | A KCNJ8 mutation associated with early repolarization and atrial fibrillation |
| Q37730875 | A common angiotensin-converting enzyme polymorphism and preoperative angiotensin-converting enzyme inhibition modify risk of tachyarrhythmias after congenital heart surgery |
| Q37626276 | A common variant on chromosome 4q25 is associated with prolonged PR interval in subjects with and without atrial fibrillation. |
| Q35633271 | A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. |
| Q35549364 | A genetic contribution to risk for postoperative junctional ectopic tachycardia in children undergoing surgery for congenital heart disease |
| Q33993646 | A genome-wide association study to identify genomic modulators of rate control therapy in patients with atrial fibrillation |
| Q37135895 | A genotype-dependent intermediate ECG phenotype in patients with persistent lone atrial fibrillation genotype ECG-phenotype correlation in atrial fibrillation |
| Q37339741 | ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodeling |
| Q38977861 | Association of the angiotensinogen M235T polymorphism with recurrence after catheter ablation of acquired atrial fibrillation |
| Q59136309 | Atrial Fibrillation Mechanisms and Implications for Catheter Ablation |
| Q56891140 | Atrial fibrillation symptom clusters and associated clinical characteristics and outcomes: A cross-sectional secondary data analysis |
| Q88386985 | Atrial fibrillation symptom profiles associated with healthcare utilization: A latent class regression analysis |
| Q36628071 | Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation |
| Q34182560 | Characterization of genome-wide association-identified variants for atrial fibrillation in African Americans |
| Q36252497 | Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation |
| Q37688211 | Common SCN10A variants modulate PR interval and heart rate response during atrial fibrillation. |
| Q36654218 | Common atrial fibrillation risk alleles at 4q25 predict recurrence after catheter-based atrial fibrillation ablation |
| Q33854824 | Common variants in KCNN3 are associated with lone atrial fibrillation |
| Q35108134 | Differential impact of race and risk factors on incidence of atrial fibrillation. |
| Q36683034 | Functional modeling in zebrafish demonstrates that the atrial-fibrillation-associated gene GREM2 regulates cardiac laterality, cardiomyocyte differentiation and atrial rhythm |
| Q36876093 | Genetic mechanisms of atrial fibrillation: impact on response to treatment |
| Q28607469 | Genetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL) |
| Q34987142 | Genetic variation in the rhythmonome: ethnic variation and haplotype structure in candidate genes for arrhythmias |
| Q37099702 | Genetics of atrial fibrillation: rare mutations, common polymorphisms, and clinical relevance |
| Q38894994 | Genotype influence in responses to therapy for atrial fibrillation |
| Q37146274 | Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation |
| Q39300535 | Lone AF - Etiologic Factors and Genetic Insights into Pathophysiolgy |
| Q35068272 | Lymphoblastoid cell lines models of drug response: successes and lessons from this pharmacogenomic model |
| Q60183578 | Mechanisms and Drug Development in Atrial Fibrillation |
| Q30156103 | Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation |
| Q33563000 | Novel genetic markers associate with atrial fibrillation risk in Europeans and Japanese |
| Q34976915 | Pharmacogenomics: the genetics of variable drug responses |
| Q37678692 | Prevalence and predictors of atrial fibrillation among patients undergoing bariatric surgery |
| Q36537035 | Relation of morbid obesity and female gender to risk of procedural complications in patients undergoing atrial fibrillation ablation. |
| Q36098696 | Relation of the severity of obstructive sleep apnea in response to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter |
| Q38936967 | Rhythm control in atrial fibrillation |
| Q36315573 | Risk factors for bradycardia requiring pacemaker implantation in patients with atrial fibrillation. |
| Q33746384 | Role of inflammation and oxidative stress in atrial fibrillation |
| Q34735964 | SCN10A/Nav1.8 modulation of peak and late sodium currents in patients with early onset atrial fibrillation |
| Q36139922 | Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation. |
| Q37469038 | The Role Of Renin Angiotensin System In Atrial Fibrillation |
| Q36264955 | The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight? |
| Q36853514 | The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS |
| Q33578278 | Whole blood gene expression and atrial fibrillation: the Framingham Heart Study |
| Q34217688 | Whole-exome sequencing in familial atrial fibrillation. |
Search more.